|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Astra_AB
gptkb:Zeneca_Group
|
|
gptkbp:ceo
|
gptkb:Pascal_Soriot
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
collaborative studies
Phase I
over 100 ongoing
|
|
gptkbp:collaborations
|
various biotech firms
|
|
gptkbp:employees
|
70,600 (2020)
|
|
gptkbp:founded
|
gptkb:1999
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_England
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Astra Zeneca Group
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
over 10,000
|
|
gptkbp:is_vulnerable_to
|
gptkb:Astra_Zeneca/_Oxford_vaccine
|
|
gptkbp:marketed_as
|
gptkb:Lynparza
gptkb:Breztri_Aerosphere
gptkb:Brilinta
gptkb:Dapagliflozin
gptkb:Faslodex
gptkb:Imfinzi
gptkb:Selumetinib
gptkb:Tagrisso
gptkb:Symbicort
gptkb:Zoladex
gptkb:Nexium
gptkb:Farxiga
gptkb:Pulmicort
gptkb:Seroquel
gptkb:Acalabrutinib
gptkb:Crestor
|
|
gptkbp:partnership
|
gptkb:University_of_Oxford
gptkb:Moderna
|
|
gptkbp:products
|
vaccines
oncology drugs
cardiovascular drugs
|
|
gptkbp:research
|
gptkb:Mene_Pangalos
|
|
gptkbp:research_and_development
|
$6.1 billion (2020)
|
|
gptkbp:research_areas
|
neurology
autoimmune diseases
infectious diseases
respiratory diseases
gastroenterology
|
|
gptkbp:revenue
|
$37 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:LSE
|
|
gptkbp:sustainability_initiatives
|
gptkb:healthcare_access
community engagement
environmental responsibility
|
|
gptkbp:symbol
|
AZN
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca_Canada_Inc.
|
|
gptkbp:bfsLayer
|
4
|